Literature DB >> 7889304

Different endothelin receptors involved in endothelin-1- and sarafotoxin S6B-induced contractions of the human isolated coronary artery.

W A Bax1, Z Aghai, C L van Tricht, C Wassenaar, P R Saxena.   

Abstract

1. Endothelin receptors, that mediate contraction of the human isolated coronary artery, were characterized by use of a number of agonists and antagonists. Contraction induced by the non-selective agonists, endothelin (ET)-1 and sarafotoxin S6b, was compared in endothelium-intact and endothelium-denuded ring segments. The effects of ET-1 and BQ-123 (an ETA receptor antagonist) were investigated both in ring segments and in spirally cut strips. Lastly, the effect of phosphoramidon was studied on contraction induced by big-ET-1. 2. The order of agonist potency (pD2) in endothelium-intact coronary artery ring segments was: ET-1 (8.27) approximately sarafotoxin S6b (8.16) > big-ET-1 (< 7.1) approximately ET-3 (< 6.9). [Ala1,3,11,15]ET-1 (ETB receptor agonist) caused significant contraction only at 1 microM, whereas 0.3 microM big-ET-3 had no effect. Removal of the endothelium in ring segments did not affect the contractile response to ET-1 or to sarafotoxin S6b. 3. After a full concentration-response curve had been obtained to ET-1 or sarafotoxin S6b, further contractions of the endothelium-intact coronary artery segments could only be achieved by applying ET-1 in segments exposed to sarafotoxin S6b, and not the reverse. 4. BQ-123 (0.1 microM) antagonized contractions of endothelium-intact ring segments induced by sarafotoxin S6b (pKB 7.86). Only 10 microM BQ-123 antagonized contractions induced by ET-1 (pKB 5.75). FR139317 was also more potent against sarafotoxin S6b (pKB 8.24-8.47) than against ET-1 (pKB 6.11). [Ala1,3,11,15]ET-1 (1 microM) had no effect on the contractile response to ET-1 or to sarafotoxin S6b. 5. In strip preparations with intact endothelium, the pD2 of ET-l increased to 9.04 =/- 0.16 (vs.8.50 +/- 0.07 in rings), and BQ-123 (1 microM) caused a rightward shift of the ET-l induced concentration response curve (pKB 6.62 vs. 5.75 in rings).6. Contractile responses to big-ET-1 of endothelium-intact coronary artery segments were attenuated in the presence of phosphoramidon (100 microM), indicating conversion of big-ET-1 to ET-1 within the coronary artery segment.7. The present study indicates that ET-1 and sarafotoxin S6b contract the human isolated coronary artery via different receptors, which can probably be best characterized as subtypes of the ETA receptor.Furthermore, it is demonstrated that the type of preparation (ring or strip) may affect the potency of ET-1 as an agonist and of BQ-123 as an antagonist.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7889304      PMCID: PMC1510484          DOI: 10.1111/j.1476-5381.1994.tb17162.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  43 in total

1.  Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor.

Authors:  M Ihara; K Noguchi; T Saeki; T Fukuroda; S Tsuchida; S Kimura; T Fukami; K Ishikawa; M Nishikibe; M Yano
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

2.  Venous smooth muscle contains vasoconstrictor ETB-like receptors.

Authors:  S Moreland; D M McMullen; C L Delaney; V G Lee; J T Hunt
Journal:  Biochem Biophys Res Commun       Date:  1992-04-15       Impact factor: 3.575

3.  Effect of endothelin on normal and diseased human coronary arteries.

Authors:  A H Chester; G S O'Neil; S P Allen; T N Luu; S Tadjkarimi; M H Yacoub
Journal:  Eur J Clin Invest       Date:  1992-03       Impact factor: 4.686

4.  BQ-123, cyclo(-D-Trp-D-Asp-Pro-D-Val-Leu), is a non-competitive antagonist of the actions of endothelin-1 in SK-N-MC human neuroblastoma cells.

Authors:  C R Hiley; D J Cowley; J T Pelton; A C Hargreaves
Journal:  Biochem Biophys Res Commun       Date:  1992-04-15       Impact factor: 3.575

5.  [Ala1,3,11,15]endothelin-1 analogs with ETB agonistic activity.

Authors:  T Saeki; M Ihara; T Fukuroda; M Yamagiwa; M Yano
Journal:  Biochem Biophys Res Commun       Date:  1991-08-30       Impact factor: 3.575

6.  Endothelium-dependent vascular activities of endothelin-like peptides in the isolated superior mesenteric arterial bed of the rat.

Authors:  S A Douglas; C R Hiley
Journal:  Br J Pharmacol       Date:  1990-09       Impact factor: 8.739

7.  Heterogeneity of endothelin-sarafotoxin receptors mediating contraction of pig coronary artery.

Authors:  V J Harrison; A Randriantsoa; P Schoeffter
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

8.  The vasoconstrictor action of big endothelin-1 is phosphoramidon-sensitive in rabbit saphenous artery, but not in saphenous vein.

Authors:  M Auguet; S Delaflotte; P E Chabrier; P Braquet
Journal:  Eur J Pharmacol       Date:  1992-11-24       Impact factor: 4.432

9.  Differences between endothelin receptors mediating contraction of guinea-pig aorta and pig coronary artery.

Authors:  P Schoeffter; A Randriantsoa
Journal:  Eur J Pharmacol       Date:  1993-11-09       Impact factor: 4.432

10.  Evidence for multiple endothelin receptors in the guinea-pig pulmonary artery and trachea.

Authors:  L O Cardell; R Uddman; L Edvinsson
Journal:  Br J Pharmacol       Date:  1992-02       Impact factor: 8.739

View more
  7 in total

1.  Contractile effect of big endothelin-1 and its conversion to endothelin-1 in rabbit cerebral arteries.

Authors:  J Petersson; G C Hanson; B F Lindberg; E D Högestätt
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-11       Impact factor: 3.000

2.  Vasoconstrictor activity of novel endothelin peptide, ET-1(1 - 31), in human mammary and coronary arteries in vitro.

Authors:  J J Maguire; R E Kuc; A P Davenport
Journal:  Br J Pharmacol       Date:  2001-11       Impact factor: 8.739

3.  ETA receptor-mediated constrictor responses to endothelin peptides in human blood vessels in vitro.

Authors:  J J Maguire; A P Davenport
Journal:  Br J Pharmacol       Date:  1995-05       Impact factor: 8.739

4.  Endothelin ET(B) receptors in arteries and veins: multiple actions in the vein.

Authors:  Nathan R Tykocki; Cheryl E Gariepy; Stephanie W Watts
Journal:  J Pharmacol Exp Ther       Date:  2009-03-18       Impact factor: 4.030

5.  Endothelin-1-induced venous contraction is maintained in DOCA-salt hypertension; studies with receptor agonists.

Authors:  Stephanie W Watts; Gregory D Fink; Carrie A Northcott; James J Galligan
Journal:  Br J Pharmacol       Date:  2002-09       Impact factor: 8.739

6.  Failure of BQ123, a more potent antagonist of sarafotoxin 6b than of endothelin-1, to distinguish between these agonists in binding experiments.

Authors:  J J Maguire; R E Kuc; B A Rous; A P Davenport
Journal:  Br J Pharmacol       Date:  1996-05       Impact factor: 8.739

Review 7.  Biomedical applications of snake venom: from basic science to autoimmunity and rheumatology.

Authors:  Carlos A Cañas; Santiago Castaño-Valencia; Fernando Castro-Herrera; Felipe Cañas; Gabriel J Tobón
Journal:  J Transl Autoimmun       Date:  2020-12-14
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.